Tuesday, October 31, 2006

Bayer - Trasylol: who knew what and when?

By Marc Greilsamer

Suppressed data? Secret informants? Fall guys? Welcome to the pharmaceutical industry, which is filled with enough mystery and intrigue to satisfy even the most demanding crime-drama aficionado. Yet, the issues that come into play in this gigantic, lucrative industry are quite real–and are certainly matters of life or death.

Questions and accusations are swirling around the German drug maker Bayer A.G., their heart-surgery drug, Trasylol (aprotinin), and the risk of potentially fatal side effects. But what distinguishes this case from most run-of-the-mill drug-safety controversies is the fact that Bayer may have withheld, either intentionally or errantly, pertinent information about Trasylol from the U.S. Food and Drug Administration.

Read the full article at newsinferno.com

No comments: